Global Pheochromocytoma Market - 2022-2029

Market Overview

The global pheochromocytoma market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Pheochromocytoma is a neuroendocrine tumor that develops from cells known as chromaffin cells. The adrenal glands contain cells that create hormones that the body needs. The adrenal glands are tiny organs that sit on top of the kidneys in the upper abdomen. The tumor releases hormones that may cause high blood pressure, headache, sweating, and panic attack symptoms. If a pheochromocytoma isn't treated, severe or life-threatening damage to other body systems can result. The treatment consists of anti-hypertensives and surgery.

Market Dynamics

Growing clinical trials by the market players for the treatment of pheochromocytoma are expected to drive market growth.

On August 12, 2021, Merck Sharp & Dohme LLC conducted a Phase 2 Study to evaluate the efficacy and safety of Belzutifan (MK-6482, Formerly PT2977) monotherapy in participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET). Moreover, National Cancer Institute (NCI), on December 2, 2021, conducted phase II trial tests on whether the combination of talazoparib and temozolomide works to shrink tumors in patients with rare cancer that have spread to other places in the body (advanced). Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Stringent government regulations, lack of availability of precise medications, and lack of awareness associated with the disease among people are some factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. COVID-19 was found in the adrenal and pituitary glands of some patients who died from the disease, indicating that these organs could be among the infection's targets. IV steroid (dexamethasone) supplementation in hospitalized patients requiring oxygen was one of the first highly effective therapy for COVID-19 infection. Moreover, according to a medical study, the adrenal system is one of the most highly affected organ systems in the body during acute active infection in patients with COVID-19 infection who require hospitalization. On the other hand, patients were subjected to significant disruptions in their care, with most appointments and treatments being canceled, curtailed, or postponed. Almost all used telemedicine to replace face-to-face visits, about half of patients undergoing treatment changes switched from hospital to home therapy, and a quarter of patients had difficulty getting their medications.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Surgery segment is expected to hold the largest market share in pheochromocytoma market

The surgery segment is expected to dominate in 2021. The primary treatment for a pheochromocytoma is surgery to remove the tumor. Pheochromocytoma is treated by surgically removing the tumor-bearing adrenal gland(s). Except for individuals with significant additional medical concerns that would prevent them from surviving an operation, this is true for practically all patients. Medical treatment can counteract the effects of adrenaline excess, although it is not as successful as surgery. For instance, Adrenalectomy is the removal of one or both adrenal glands. The tissues and lymph nodes inside the belly will be evaluated during this surgery, and if the tumor has spread, these tissues are also removed. Therefore, it has increased the demand for surgery. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global pheochromocytoma market

In 2021, North America accounted for the highest revenue share. The high prevalence of pheochromocytoma, increasing clinical trials by the market players, rising geriatric population, well-established infrastructure, and advancement in the diagnosis of the diseases are factors the market is expected to boost in the forecast period. For instance, In the USA, the prevalence of pheochromocytoma ranges from 0.2 to 0.8 per 100,000 persons. Moreover, pheochromocytoma in patients with hypertension in general outpatient clinics is about 0.1%. Additionally, pheochromocytoma affects about 5% of patients with adrenal tumors detected by accident on imaging. Individuals with a germline mutation in pheochromocytoma susceptibility genes may have a 50% chance of developing pheochromocytoma. Also, the gene expression profiling of various tumors has provided new subtype-specific options for targeted therapies. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the pheochromocytoma market are Septodont, Abbott Laboratories, Jubilant Cadista Pharmaceuticals Inc., Pfizer Inc., ANI Pharmaceuticals, Inc., WellSpring Pharmaceutical Corporation, Valeant Pharmaceuticals North America LLC. Hikma Pharmaceuticals PLC, Progenics Pharmaceuticals, Inc. and Baxter.

Progenics Pharmaceuticals, Inc.:

Overview:

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients who have cancer and related conditions. The company is focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including therapeutic agents designed to treat cancer (AZEDRA, 1095, and PSMA TTC); prostate-specific membrane antigen ("PSMA") targeted imaging agents for prostate cancer (PyL and 1404); and imaging analysis technology (aBSI and PSMA AI).

­Product Portfolio:

AZEDRA (iobenguane I 131): AZEDRA (iobenguane I 131) is a prescription medicine used to treat adult and pediatric patients 12 years and older with cancers known as pheochromocytoma and paraganglioma that are positive for the norepinephrine transporter (as determined by an iobenguane scan), and who require systemic anticancer therapy.

Why Purchase the Report?

Visualize the composition of the pheochromocytoma market segmentation by diagnosis, treatment, end user, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in pheochromocytoma market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of pheochromocytoma market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global pheochromocytoma market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers